Evaluation of the MD Anderson tumor score for diffuse large B‐cell lymphoma in the rituximab era

OBJECTIVES: Diffuse large B‐cell lymphoma (DLBCL) is an aggressive heterogeneous lymphoma with standard treatment. However, 30%‐40% of patients still fail, so we should know which patients are candidates for alternative therapies. IPI is the main prognostic score but, in the rituximab era, it cannot...

Descripción completa

Detalles Bibliográficos
Autores principales: Gutierrez, Antonio, Bento, Leyre, Diaz‐Lopez, Antonio, Barranco, Gilberto, Garcia‐Recio, Marta, Lopez‐Guillermo, Armando, Dlouhy, Ivan, Rovira, Jordina, Rodriguez, Mario, Sanchez Pina, Jose María, Baile, Monica, Martín, Alejandro, Novelli, Silvana, Sancho, Juan‐Manuel, García, Olga, Salar, Antonio, Bastos‐Oreiro, Mariana, Rodriguez‐Salazar, Mª José, Fernandez, Ruben, de la Cruz, Fatima, Queizan, Jose Antonio, González de Villambrosia, Sonia, Cordoba, Raul, López, Andres, Luzardo, Hugo, García, Daniel, Sastre‐Serra, Jordi, Garcia, Juan Fernando, Montalban, Carlos, Cabanillas, Fernando, Rodríguez, Jose
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7217048/
https://www.ncbi.nlm.nih.gov/pubmed/31804029
http://dx.doi.org/10.1111/ejh.13364

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7217048/
https://www.ncbi.nlm.nih.gov/pubmed/31804029
http://dx.doi.org/10.1111/ejh.13364

Ejemplares similares